Myogen Inc. About
Myogen Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the treatment
of cardiovascular disorders. Myogen currently markets one product
in Europe, Perfan I.V., for the treatment of acute decompensated
heart failure,
and they have three product candidates in late-stage clinical development: enoximone
capsules for the treatment of chronic
heart failure, ambrisentan for the treatment of pulmonary arterial hypertension
and darusentan for the treatment of resistant systolic hypertension. Myogen,
in partnership with Novartis, also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the treatment
of chronic heart failure and related cardiovascular disorders. Perfan
I.V.-- Acute Deompensated Heart Failure Marketed Enoximone
Capsules -- Advanced Chronic
Heart Failure Ambrisentan -- Pulmonary
Arterial
Hypertension Darusentan -- Uncontrolled
Hypertension
More
on Myogen